🔗 Visit the ClinicalTrials.gov page for NCT00988741
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Lancet Oncol | 2012 | 3.88 |
| 2 | Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. | Oncotarget | 2012 | 1.55 |
| 3 | Targeting the HGF/Met signaling pathway in cancer therapy. | Expert Opin Ther Targets | 2012 | 1.45 |
| 4 | Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. | World J Hepatol | 2013 | 1.23 |
| 5 | MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. | World J Gastroenterol | 2015 | 0.84 |
| 6 | Targeted therapies in the treatment of advanced hepatocellular carcinoma. | Clin Med Insights Oncol | 2013 | 0.83 |